摘要
目的探讨通天口服液联合替罗非班对小动脉闭塞型进展性卒中患者的疗效及机制。方法将2020年1月至2021年12月徐州医科大学附属医院神经内科收治的小动脉闭塞型进展性卒中患者分为治疗组和对照组,每组40例。对照组使用替罗非班注射液治疗,治疗组使用替罗非班联合通天口服液治疗。通过对比治疗前后美国国立卫生院卒中量表(NIHSS)评分、炎症因子[C-反应蛋白(CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)]和血小板功能指标[血小板黏附试验(PAdT)和血小板聚集试验(PAgT)]情况评价2组的临床疗效,并观察2组不良事件发生情况。结果治疗前,2组在NIHSS评分、炎症因子水平和血小板功能指标上比较,差异均无统计学意义(P>0.05)。治疗2周后,2组NIHSS评分、炎症因子(CRP、IL-6、TNF-α)、血小板功能指标(PAdT和PAgT)降低,且治疗组的上述指标改善幅度显著优于对照组,差异均有统计学意义(P<0.05)。在治疗期间,2组不良事件的发生率比较,差异无统计学意义(P>0.05)。结论通天口服液联合替罗非班可改善小动脉闭塞型进展性卒中患者的神经功能和血小板功能,抑制炎症反应,减轻脑组织炎性损伤,且安全性良好。
Objective To investigate the efficacy and mechanism of tongtian oral liquid combined with tirofiban in patients with small artery occlusive progressive stroke.Methods The patients with small artery occlusive progressive stroke admitted to the Department of Neurology,Affiliated Hospital of Xuzhou Medical University from January 2020 to December 2021 were divided into treatment group and control group,with 40 cases in each group.The control group was treated with tirofiban injection,and the treatment group was treated with tirofiban combined with tongtian oral liquid.The clinical efficacy of the two groups was evaluated by comparing the National Institutes of Health Stroke Scale(NIHSS)score,inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)]and platelet function indexes[platelet adhesion test(PAdT)and platelet aggregation test(PAgT)]before and after treatment,and the occurrence of adverse events in the two groups was observed.Results Before treatment,there was no significant difference being found in the comparison of NIHSS score,levels of inflammatory factors and platelet function indexes between the two groups(P>0.05).After 2 weeks of treatment,the NIHSS score,inflammatory factors(CRP,IL-6,TNF-α),platelet function indexes(PAdT and PAgT)in the two groups were decreased,and the improvement of the above indexes in the treatment group were significantly better than those in the control group,the differences were statistic ally significant(P<0.05).During the treatment,there was no significant difference in the comparison of the incidence of adverse events between the two groups(P>0.05).Conclusion Tongtian oral liquid combined with tirofiban can improve the neurological function and platelet function of patients with small artery occlusive progressiv e stroke,inhibit inflammatory response,reduce inflammatory injury of brain tissue,and has good safety.
作者
房效莉
阚姝
魏礼梅
FANG Xiaoli;KAN Shu;WEI Limei(Department of Neurology,Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu 221004,China;Department of Neurology,the First People′s Hospital of Sihong County,Suqian,Jiangsu 223900,China)
出处
《现代医药卫生》
2025年第10期2307-2309,2315,共4页
Journal of Modern Medicine & Health
基金
宿迁市科学技术局2023年度市级指导性科技计划项目(Z202346)。
关键词
通天口服液
替罗非班
小动脉闭塞型进展性卒中
炎症因子
血小板功能
Tongtian oral liguid
Tirofiban
Small artery occlusive progressive stroke
Inflammatory markers
Platelet function
